GSH Cancer Research Results

GSH, Glutathione: Click to Expand ⟱
Source:
Type:
Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress.
Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system.
cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment.
While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied.
Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy.
Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death.
Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion.
Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS).

"...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..."
"Cancer cells have a high level of GSH compared to normal cells."
"...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy."

The loss of GSH is broadly known to be directly related to the apoptosis progression.
Scientific Papers found: Click to Expand⟱
1722- SFN,    Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems
- Review, Var, NA
TumCCA↑, CYP1A1↓, CYP3A4↓, Cyt‑c↑, Casp9↑, Apoptosis↑, ROS↑, MAPK↑, P53↑, BAX↑, ChemoSen↑, HDAC↓, GSH↓, HO-1↑,
3946- Shank,    Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies
- Review, AD, NA
*neuroP↑, *cognitive↑, *AChE↓, *antiOx↑, *GSR↑, *SOD↑, *GSH↑, *Inflam↓, *ROS↓, *lipid-P↓, *cardioP↑,
3300- SIL,    Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy
- Review, Var, NA
*ROS↓, *SOD↑, *hepatoP↑, *AST↓, *ALAT↓, *lipid-P↓, *GSH↑, *Catalase↑, *GSTs↑, *GSR↑, *TNF-α↓, *IFN-γ↓, *IL4↓, *IL2↓, *NF-kB↓, *IL10↑, *Inflam↓, COX2/PTGS2↓, Apoptosis↑, ChemoSen↑, PGE2↓, VEGF↓,
3307- SIL,    Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications
- Review, Var, NA
*NRF2↑, *antiOx↑, *chemoP↑, *Inflam↓, *BioAv↑, eff↑, *NQO1↑, TNF-α↓, IL6↓, *GSH↑, *ROS↓, *MDA↓, eff↑, *hepatoP↑, *GPx↑, *SOD↑, *Catalase↑, *HO-1↑, *neuroP↑,
3309- SIL,    Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
- Review, NA, NA
*ROS↓, *IronCh↑, *MMP↑, *NRF2↑, *Inflam↓, *hepatoP↑, *HSPs↑, *Trx↑, *SIRT2↑, *GSH↑, *ROS↑, *NADPH↓, *iNOS↓, *NF-kB↓, *BioAv↓, *Dose↝, *BioAv↑,
3311- SIL,    Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells
- in-vitro, Nor, PC12
*antiOx↑, *Inflam↓, AntiCan↑, *ROS↓, *MDA↓, *GSH↓, *NRF2↑, *GPx↑, *GCLC↑, *GCLM↑,
3295- SIL,    Hepatoprotective effect of silymarin
- Review, NA, NA
*hepatoP↑, *ROS↓, *GSH↑, *BioAv↝, ERK↓, NF-kB↓, STAT3↓, COX2/PTGS2↓, Inflam↓, IronCh↑, lipid-P↓, ALAT↓, AST↓, TNF-α↓, *α-SMA↓, *SOD↑,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2/PTGS2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27/CDKN1B↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31/PECAM-1↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3655- SIL,    Protective effect of silymarin on oxidative stress in rat brain
- in-vivo, AD, NA
*GSH↑, *VitC↑, *SOD↑, *lipid-P↓, *ROS↓, *hepatoP↑, *neuroP↑,
3654- SIL,    Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain
- in-vivo, AD, NA
*ROS↓, *neuroP↑, *GSH↑, *SOD↑,
3653- SIL,    Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress
- in-vivo, AD, NA
*hepatoP↑, *neuroP↑, *cognitive↑, *memory↑, *Inflam↓, *GSH↑, *MDA↓, *Inflam↓, *antiOx↓,
3648- SIL,    Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
- Review, NA, NA
*antiOx↑, *Inflam↓, *lipid-P↓, *necrosis↓, *hepatoP↑, *IL1↓, *IL6↓, *TNF-α↓, *IFN-γ↓, MAPK↓, Apoptosis↑, Cyt‑c↑, Casp3↑, Casp9↑, *PPARγ↑, *GLUT4↑, *HSPs↓, *HSP27↑, *Trx↑, *SIRT1↑, *ALAT↓, *GSH↑, *lipid-P↓, *TNF-α↓, TumCG↓, P21↑, CDK4↑,
3646- SIL,    "Silymarin", a promising pharmacological agent for treatment of diseases
- Review, NA, NA
*P-gp/ABCB1↓, *Inflam↓, *hepatoP↑, *antiOx↑, *GSH↑, *BioAv↑, *SOD↑, *IFN-γ↓, *IL4↓, *IL10↓, *Half-Life↓, *TNF-α↓, *ALAT↓, *AST↓, Akt↓, chemoP↑, β-catenin/ZEB1↓, TumCP↓, MMP↓, Cyt‑c↑, *RenoP↑, *BBB↑,
3313- SIL,    Silymarin attenuates post-weaning bisphenol A-induced renal injury by suppressing ferroptosis and amyloidosis through Kim-1/Nrf2/HO-1 signaling modulation in male Wistar rats
- in-vivo, NA, NA
*NRF2↑, *HO-1↑, *creat↓, *BUN↓, *RenoP↑, *MDA↓, *TNF-α↓, *IL1β↓, *Cyt‑c↓, *Casp3↓, *GSTs↓, *GSH↑, *GPx4↑, *SOD↑, *GSR↓, *Ferroptosis↓,
3319- SIL,    Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *BBB?, *tau↓, *NF-kB↓, *IL1β↓, *TNF-α↓, *IL4↓, *MAPK↓, *memory↑, *cognitive↑, *Aβ↓, *ROS↓, *lipid-P↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *AChE↓, *BChE↓, *p‑ERK↓, *p‑JNK↓, *p‑p38↓, *GutMicro↑, *COX2/PTGS2↓, *iNOS↓, *TLR4↓, *neuroP↑, *Strength↑, *AMPK↑, *MMP↑, *necrosis↓, *NRF2↑, *HO-1↑,
3318- SIL,    Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight
- Review, AD, NA - Review, Park, NA
*hepatoP↑, *neuroP↑, *TLR4↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *memory↑, *cognitive↑, *NRF2↑, *HO-1↑, *ROS↓, *Akt↑, *mTOR↑, *SOD↑, *Catalase↑, *GSH↑, *IL10↑, *IL6↑, *NO↓, *MDA↓, *AChE↓, *MAPK↓, *BDNF↑,
3315- SIL,    Silymarin alleviates docetaxel-induced central and peripheral neurotoxicity by reducing oxidative stress, inflammation and apoptosis in rats
- in-vivo, Nor, NA
neuroP↑, *NRF2↑, *HO-1↑, *lipid-P↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *NF-kB↓, *TNF-α↓, *JNK↓, *Bcl-2↑, *BAX↑,
3314- SIL,    Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review
- Review, NA, NA
*antiOx↑, *hepatoP↑, *Half-Life↑, *ROS↓, *GSH↑, *hepatoP↑, *lipid-P↓, *TNF-α↓, *IFN-γ↓, *IL2↓, *IL4↓, *NF-kB↓, *iNOS↓, *OATPs↓, *OCT4↓, *Inflam↓, *PGE2↓, MMPs↓, VEGF↓, angioG↓, STAT3↓, *ALAT↓, *AST↓, Dose↝,
4205- SIL,    The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review
- Review, AD, NA
*BDNF↑, *5HT↑, *MDA↓, *GSH↑, *SOD↑, *Catalase↑, *IL6↓, *IL1β↓,
2410- SIL,    Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vivo, NA, NA
TumAuto↑, ATP↓, Glycolysis↓, H2O2↑, P53↑, GSH↓, xCT/SLC7A11↓, BNIP3↝, MMP↑, mt-ROS↑, mtDam↑, HK2↓, PFKP↓, PKM2↓, TumCG↓,
2362- SK,    RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide
- in-vitro, GBM, U87MG - in-vivo, GBM, NA - in-vitro, GBM, U251
RIP1↑, RIP3↑, Glycolysis↓, G6PD↓, HK2↓, PKM2↓, H2O2↑, GSH↓, ROS↑,
2188- SK,    Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment
- Review, Var, NA
ROS↑, EGFR↓, PI3K↓, Akt↓, angioG↓, Apoptosis↑, Necroptosis↑, GSH↓, Ca+2↓, MMP↓, ERK↓, p38↑, proCasp3↑, eff↓, VEGF↓, FOXO3↑, EGR1↑, SIRT1↑, RIP1↑, RIP3↑, BioAv↓, NF-kB↓, Half-Life↓,
2203- SK,    Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation
- in-vitro, Lung, NA
TumCP↓, Apoptosis↓, TumCMig↓, TumCI↓, Ferroptosis↑, ERK↓, GPx4↓, 4-HNE↑, ROS↑, GSH↓, ATF3↑, HDAC1↓, ac‑Histones↑,
2225- SK,    Shikonin protects skin cells against oxidative stress and cellular dysfunction induced by fine particulate matter
- in-vitro, Nor, HaCaT
*antiOx↑, *ROS↓, *GSH↑, *GCLC↑, *GSS↑, *Akt↑, *NRF2↑,
2220- SK,    Shikonin Alleviates Gentamicin-Induced Renal Injury in Rats by Targeting Renal Endocytosis, SIRT1/Nrf2/HO-1, TLR-4/NF-κB/MAPK, and PI3K/Akt Cascades
- in-vivo, Nor, NA
*RenoP↑, *ROS↓, *SIRT1↓, *NRF2↑, *HO-1↑, *GSH↑, *TAC↑, *SOD↑, *MDA↓, *NO↓, *iNOS↓, *NHE3↑, *PI3K↑,
2215- SK,  doxoR,    Shikonin alleviates doxorubicin-induced cardiotoxicity via Mst1/Nrf2 pathway in mice
- in-vivo, Nor, NA
*cardioP↑, *ROS↓, *Inflam↓, *Mst1↓, *NRF2↑, *eff↓, *antiOx↑, *SOD↑, *GSH↑, *TNF-α↓, BAX↓, Bcl-2↑,
2214- SK,    Shikonin Attenuates Cochlear Spiral Ganglion Neuron Degeneration by Activating Nrf2-ARE Signaling Pathway
- in-vitro, Nor, NA
*NRF2↑, *HO-1↑, *NQO1↑, *antiOx↑, *neuroP↑, *ROS↓, *MDA↓, *SOD↑, GSH↑,
2202- SK,    Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification
- in-vitro, Var, NA
Iron↑, Ferroptosis↑, pH↝, H2O2↑, ROS↑, Fenton↑, GSH↓, GPx4↓, lipid-P↑,
3042- SK,    The protective effects of Shikonin on lipopolysaccharide/D -galactosamine-induced acute liver injury via inhibiting MAPK and NF-kB and activating Nrf2/HO-1 signaling pathways
- in-vivo, Nor, NA
*TNF-α↓, *IL1β↓, *IL6↓, *IFN-γ↓, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *JNK↓, *ERK↓, *p38↓, *NF-kB↓, *p‑IKKα↓, *SOD↑, *GSH↑, *HO-1↑, *NRF2↑, *hepatoP↑,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
1284- SK,    Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy
- in-vitro, Melanoma, RPMI-8226 - in-vitro, Melanoma, U266
Ferroptosis↑, LDH↓, ROS↑, Iron↑, lipid-P↑, ATP↓, HMGB1↓, GPx4↓, MDA↑, SOD↓, GSH↓,
2011- SK,    Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3β Signaling
- in-vitro, Nor, HL7702 - in-vivo, Nor, NA
*NRF2↑, *hepatoP↑, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *GSH↑,
1342- SK,    RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species
- in-vitro, GBM, NA - in-vivo, NA, NA
RIP1↑, RIP3↑, DNAdam↑, ROS↑, GSH↓,
1343- SK,    Simple ROS-responsive micelles loaded Shikonin for efficient ovarian cancer targeting therapy by disrupting intracellular redox homeostasis
- in-vitro, Ovarian, A2780S - in-vivo, NA, A2780S
*BioAv↓, ROS↑, GSH↓, TumCG↓,
1344- SK,    Novel multiple apoptotic mechanism of shikonin in human glioma cells
- in-vitro, GBM, U87MG - in-vitro, GBM, Hs683 - in-vitro, GBM, M059K
ROS↑, GSH↓, MMP↓, P53↑, cl‑PARP↑, Catalase↓, SOD1↑, Bcl-2↓, BAX↑, eff↓,
1345- SK,    The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway
- in-vitro, AML, HL-60
CD14↑, CD11b↑, ROS↑, GSH↓, GSH/GSSG↓, GPx↑, Catalase↓, Diff↑,
1346- SK,    An Oxidative Stress Mechanism of Shikonin in Human Glioma Cells
- in-vitro, GBM, U87MG - in-vitro, GBM, Hs683
NRF2↓, ROS↑, Apoptosis↑, Cyt‑c↑, GSH↓, MMP↓, P53↑, HO-1⇅,
1512- Squ,    Combination therapy in combating cancer
- Review, NA, NA
ChemoSideEff↓, *ROS↓, *GSH↑, eff↑, chemoP↑,
4731- SSE,    Dietary selenium mitigates cadmium-induced apoptosis and inflammation in chicken testicles by inhibiting oxidative stress through the activation of the Nrf2/HO-1 signaling pathway
- in-vivo, Nor, NA
*ROS↓, *MDA↓, *H2O2↓, *Catalase↑, *GSH↑, *NRF2↑, *HO-1↑, *Bcl-2↑, *other↝,
5078- SSE,  Rad,    Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
- Trial, Pca, NA
Half-Life↝, OS↑, Pain↓, PSA↓, GSH↓, ROS↑, selectivity↑, TumCG↓, AR↓, Dose↑, ChemoSen↑, RadioS↑,
5091- SSE,    Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite
- in-vitro, GBM, U87MG - in-vitro, Cerv, HeLa - in-vitro, BC, MCF7 - in-vitro, Pca, PC3 - in-vitro, CRC, HT-29 - in-vitro, Nor, SVGp12
Ferroptosis↑, xCT/SLC7A11↓, GSH↓, GPx4↓, Iron↑, lipid-P↑, ROS↑, eff↓, TumCP↓, TumCD↑,
5093- SSE,    Pharmacological mechanisms of the anticancer action of sodium selenite against peritoneal cancer in mice
- in-vivo, Var, NA
AntiCan↑, eff↑, selectivity↑, ROS↑, Dose↝, Trx↓, GSH↓,
5106- SSE,  GSH,    Dual role of glutathione in selenite-induced oxidative stress and apoptosis in human hepatoma cells
- in-vitro, Liver, HepG2
ROS↑, Apoptosis↑, eff↑, GSH↓,
5094- SSE,    Sodium Selenite Prevents Matrine-Induced Nephrotoxicity by Suppressing Ferroptosis via the GSH-GPX4 Antioxidant System
- vitro+vivo, Nor, NRK52E
*GPx4↑, *xCT/SLC7A11↑, *GSH↑, *RenoP↑,
5092- SSE,    Redox-Active Selenium Compounds—From Toxicity and Cell Death to Cancer Treatment
- Review, Var, NA
*antiOx↑, ROS↑, GSH↓, BioAv↓,
5090- SSE,    Sodium Selenite Induces Ferroptosis in Non-small Cell Lung Cancer A549 Cells Via Reactive Oxygen Species (ROS)/Glutathione (GSH)/Glutathione Peroxidase4 (GPx4) Axis
- NA, Lung, A549
TumCP↓, ROS↑, GSH↓, MMP↓, GPx4↓, Iron↑,
5089- SSE,  Se,    Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line
- in-vitro, Pca, LNCaP
ROS↑, mtDam↑, TumCD↑, Apoptosis↑, TumCCA↑, Trx↓, angioG↓, GSH⇅, NADPH↓, GPx↑,
5088- SSE,    Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite
- in-vitro, BC, MCF7 - in-vitro, GBM, U87MG - in-vitro, Pca, PC3 - in-vitro, Cerv, HeLa - in-vitro, GBM, A172
Ferroptosis↑, ROS↑, Iron↑, xCT/SLC7A11↓, GSH↓, GPx4↓, lipid-P↑, TumCP↓, selectivity↑,
5084- SSE,  GEM,    The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study
- in-vitro, PC, PANC1 - vitro+vivo, PC, Panc02
tumCV↓, ChemoSen↑, TumCG↓, OS↑, MMP↓, AIF↑, GSH↓, Trx↓, ROS↑, AntiTum↑,

Showing Research Papers: 501 to 550 of 600
Prev Page 11 of 12 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 600

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

4-HNE↑, 1,   ATF3↑, 1,   Catalase↓, 2,   CYP1A1↓, 2,   Fenton↑, 1,   Ferroptosis↑, 5,   GPx↑, 2,   GPx4↓, 6,   GSH↓, 22,   GSH↑, 2,   GSH⇅, 1,   GSH/GSSG↓, 1,   H2O2↑, 3,   HO-1↑, 1,   HO-1⇅, 1,   Iron↑, 5,   lipid-P↓, 2,   lipid-P↑, 4,   MDA↑, 1,   NRF2↓, 1,   ROS↑, 22,   mt-ROS↑, 1,   SOD↓, 1,   SOD1↑, 1,   Trx↓, 3,   TrxR↓, 1,   xCT/SLC7A11↓, 3,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 2,   MEK↓, 1,   MMP↓, 9,   MMP↑, 1,   mtDam↑, 2,   Raf↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   cMyc↓, 2,   CYP3A4↓, 1,   G6PD↓, 1,   Glycolysis↓, 3,   ac‑Histones↑, 1,   HK2↓, 2,   LDH↓, 1,   NADPH↓, 1,   PFKP↓, 1,   PKM2↓, 3,   SIRT1↑, 1,   SIRT2↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 8,   BAX↓, 1,   BAX↑, 4,   Bcl-2↓, 3,   Bcl-2↑, 1,   Bcl-xL↓, 1,   BIM↓, 1,   Casp↑, 1,   Casp3↑, 2,   proCasp3↑, 1,   Casp9↑, 2,   Cyt‑c↑, 6,   Ferroptosis↑, 5,   iNOS↓, 1,   MAPK↓, 2,   MAPK↑, 1,   Necroptosis↑, 1,   p27/CDKN1B↑, 1,   p38↑, 1,   RIP1↑, 3,   survivin↓, 2,   TumCD↑, 2,   YAP/TEAD↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HATs↑, 1,   p‑pRB↓, 1,   tumCV↓, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

BNIP3↝, 1,   LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 6,   cl‑PARP↑, 1,   PCNA↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   CDK4↑, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 1,   P21↑, 3,   RB1↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↑, 1,   EMT↓, 1,   ERK↓, 6,   FOXO3↑, 1,   HDAC↓, 2,   HDAC1↓, 1,   mTOR↓, 1,   NOTCH1↓, 1,   PI3K↓, 2,   STAT3↓, 2,   TumCG↓, 5,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   CD11b↑, 1,   CD31/PECAM-1↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 2,   RIP3↑, 3,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 6,   TumMeta↓, 2,   uPA↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   EGFR↓, 2,   EGR1↑, 1,   Hif1a↓, 3,   LOX1↓, 1,   TAMS↝, 1,   VEGF↓, 4,   VEGFR2/KDR/Flk1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   COX2/PTGS2↓, 3,   CXCR4↓, 1,   HMGB1↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IL1↓, 1,   IL10↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL6↓, 1,   Inflam↓, 3,   MDSCs↓, 1,   NF-kB↓, 3,   PGE2↓, 1,   PSA↓, 2,   TNF-α↓, 3,  

Cellular Microenvironment(tgid=17) ⓘ

pH↝, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   ChemoSen↑, 4,   Dose↑, 1,   Dose↝, 2,   eff↓, 3,   eff↑, 5,   Half-Life↓, 1,   Half-Life↝, 2,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AR↓, 1,   AST↓, 1,   EGFR↓, 2,   IL6↓, 1,   LDH↓, 1,   PSA↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 4,   ChemoSideEff↓, 1,   hepatoP↑, 2,   neuroP↑, 2,   OS↑, 2,   Pain↓, 1,  
Total Targets: 169

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 11,   Catalase↑, 7,   Ferroptosis↓, 1,   GCLC↑, 2,   GCLM↑, 1,   GPx↑, 3,   GPx4↑, 2,   GSH↓, 1,   GSH↑, 24,   GSR↓, 1,   GSR↑, 2,   GSS↑, 1,   GSTs↓, 1,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 9,   lipid-P↓, 9,   MDA↓, 10,   MPO↓, 2,   NQO1↑, 2,   NRF2↑, 14,   ROS↓, 20,   ROS↑, 1,   SOD↑, 16,   TAC↑, 1,   Trx↑, 2,   VitC↑, 1,   xCT/SLC7A11↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 6,   AMPK↑, 1,   BUN↓, 1,   NADPH↓, 1,   PPARγ↑, 1,   SIRT1↓, 1,   SIRT1↑, 1,   SIRT2↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 2,   Apoptosis↓, 1,   BAX↑, 1,   Bcl-2↑, 2,   Casp3↓, 1,   Cyt‑c↓, 1,   Ferroptosis↓, 1,   iNOS↓, 4,   JNK↓, 2,   p‑JNK↓, 1,   MAPK↓, 2,   necrosis↓, 2,   p38↓, 1,   p‑p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP27↑, 1,   HSPs↓, 1,   HSPs↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   p‑ERK↓, 1,   Mst1↓, 1,   mTOR↑, 1,   OCT4↓, 1,   PI3K↑, 1,  

Migration(tgid=13) ⓘ

α-SMA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB?, 1,   BBB↑, 1,   GLUT4↑, 1,   NHE3↑, 1,   OATPs↓, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IFN-γ↓, 5,   p‑IKKα↓, 1,   IL1↓, 1,   IL10↓, 1,   IL10↑, 2,   IL1β↓, 5,   IL2↓, 2,   IL4↓, 4,   IL6↓, 3,   IL6↑, 1,   Inflam↓, 12,   NF-kB↓, 7,   PGE2↓, 1,   TLR4↓, 2,   TNF-α↓, 11,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   AChE↓, 3,   BChE↓, 1,   BDNF↑, 2,   tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 3,   BioAv↝, 1,   Dose↝, 1,   eff↓, 1,   Half-Life↓, 1,   Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 6,   AST↓, 5,   creat↓, 1,   GutMicro↑, 1,   IL6↓, 3,   IL6↑, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 2,   chemoP↑, 1,   cognitive↑, 4,   hepatoP↑, 13,   memory↑, 3,   neuroP↑, 9,   RenoP↑, 4,   Strength↑, 1,   toxicity↓, 1,  
Total Targets: 115

Scientific Paper Hit Count for: GSH, Glutathione
32 Thymoquinone
28 Curcumin
21 Silver-NanoParticles
21 Quercetin
20 Piperlongumine
19 Silymarin (Milk Thistle) silibinin
18 Alpha-Lipoic-Acid
17 Shikonin
14 Radiotherapy/Radiation
13 Sulforaphane (mainly Broccoli)
12 Resveratrol
12 Phenethyl isothiocyanate
11 Sulfasalazine
11 Selenite (Sodium)
10 Cisplatin
10 Allicin (mainly Garlic)
10 Artemisinin
10 Boron
10 Chrysin
10 Rosmarinic acid
9 Selenium
9 Lycopene
8 Chemotherapy
8 diet Methionine-Restricted Diet
8 Juglone
8 Luteolin
7 3-bromopyruvate
7 Ashwagandha(Withaferin A)
7 Propolis -bee glue
7 Selenium NanoParticles
6 Betulinic acid
6 Chlorogenic acid
6 Carvone
6 Copper and Cu NanoParticles
6 Eugenol
6 Gallic acid
6 Propyl gallate
5 Apigenin (mainly Parsley)
5 Melatonin
5 Baicalein
5 erastin
5 Rutin
5 Carvacrol
5 D-limonene
5 Ferulic acid
5 Hyperoside
5 Vitamin C (Ascorbic Acid)
4 Berberine
4 Carnosic acid
4 Crocetin
4 Emodin
4 Fisetin
4 Honokiol
4 doxorubicin
4 Kaempferol
4 Magnetic Fields
4 Parthenolide
3 2-DeoxyGlucose
3 Auranofin
3 chitosan
3 Cysteamine
3 Isoliquiritigenin
3 Licochalcone A
3 Piperine
3 Pterostilbene
3 Aflavin-3,3′-digallate
3 Turmerones
2 Anethole/trans-Anethole
2 Ascorbyl Palmitate
2 Beta-Caryophyllene
2 Bromelain
2 brusatol
2 α-Bisabolol / Chamomile oil
2 buckwheat sprouts
2 Caffeic acid
2 Caffeic Acid Phenethyl Ester (CAPE)
2 Thymol-Thymus vulgaris
2 Centella asiatica / Gotu kola → asiaticoside
2 Gemcitabine (Gemzar)
2 Chocolate
2 Cichoric acid / Chicoric acid
2 Cynara scolymus/Globe Artichoke/Artichoke Extract
2 Date Fruit Extract
2 Docetaxel
2 Dandelion Root
2 Ellagic acid
2 EGCG (Epigallocatechin Gallate)
2 Sesame seeds and Oil
2 Formononetin
2 Fucoidan
2 Geraniol
2 Ginger/6-Shogaol/Gingerol
2 Hydrogen Gas
2 Hibiscus sabdariffa
2 HydroxyTyrosol
2 isoorientin
2 Isovitexin
2 Lactoferrin/Talactoferrin
2 Magnetic Field Rotating
2 Methylsulfonylmethane
2 salinomycin
2 Vitexin
1 1,8-Cineole
1 cetuximab
1 Anthocyanins
1 Astragalus
1 Photodynamic Therapy
1 Camptothecin
1 Glucose
1 Ajoene (compound of Garlic)
1 Acetyl-l-carnitine
1 Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry
1 Andrographis
1 Aloe anthraquinones
1 Baicalin
1 Ras-selective lethal 3
1 Boswellia (frankincense)
1 Butyrate
1 Capsaicin
1 Cat’s Claw
1 chemodynamic therapy
1 chaetocin
1 Chlorophyllin
1 Zinc
1 Chyawanprash
1 Cinnamon
1 Citric Acid
1 Coenzyme Q10
1 Carica papaya leaf extract
1 Black phosphorus
1 SonoDynamic Therapy UltraSound
1 Cucurbitacin
1 Galantamine
1 Cynaropicrin
1 Exercise
1 Shilajit/Fulvic Acid
1 Gambogic Acid
1 Garcinol
1 Ginkgo biloba
1 Ginkgetin
1 γ-linolenic acid (Borage Oil)
1 Graviola
1 Hydroxycinnamic-acid
1 Hyperthermia
1 Isobavachalcone
1 Butein
1 Scopoletin
1 isoquercitrin
1 Lapatinib
1 Lapachol
1 Geldanamycin
1 Lemongrass Extract/Citral
1 Metformin
1 Moringa oleifera
1 Mushroom Lion’s Mane
1 Myricetin
1 N-Acetyl-Cysteine
1 Naringin
1 Nimbolide
1 Oleuropein
1 Phenylbutyrate
1 Plumbagin
1 Orlistat
1 Scoulerine
1 polyethylene glycol
1 Anti-oxidants
1 Shankhpushpi
1 Squalene
1 Glutathione
1 Taurine
1 methotrexate
1 Ursolic acid
1 Urolithin
1 Vitamin B12
1 Folic Acid, Vit B9
1 immunotherapy
1 VitK3,menadione
1 Vitamin K2
1 probiotics
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:137  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page